Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

Novo Nordisk's growth in diabetes and obesity care makes it a strong buy. Click here for a full investment analysis of NVO ...

Now, it’s worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 184% for ...

Novo Nordisk faces challenges but offers growth potential through a weight loss pill and global expansion. Read more on why ...

Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...

The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...

The US Food and Drug Administration (FDA) has granted de novo authorisation to Artera’s ArteraAI Prostate software. This ...

Novo Nordisk (NYSE: NVO) is quite the divisive stock among both investors and analysts these days. Although its high-profile ...

The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

Novo Nordisk ( ($NVO) ) has shared an update. On August 8, 2025, Novo Nordisk disclosed transactions involving the sale of shares by board members ...

Novo Nordisk A/S (NYSE:NVO) is one of the best falling stocks to buy now. On August 7, HSBC maintained a “Hold” rating on ...